Return to homepagePandemic Pact

COMBAT COVID-19 - induced adult respiratory distress syndrome

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    Innovationsfonden Denmark

  • Research Location

    Denmark

  • Lead Research Institution

    Rigshospitalet, Nordsjællands Hospital Bispebjerg Hospital, Herlev Hospital, Hvidovre Hospital, BioPorto AS, Endothel Pharma Ap

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Supportive care, processes of care and management

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

More than 50% of COVID-19 infected patients with acute lung failure and in need of respiratory therapy do not survive. This is due to damage to the body's smallest vessel (capillaries) and the severity of capillary damage can be measured with a biomarker called thrombomodulin (TM). Previous studies have shown that patients with severe organ failure (including lung failure) had a high level of TM and that this could be reduced by treatment with prostacylin (Iloprost). The project will test whether prostacyclin (Iloprost) improves lung function, thus reducing the need for respiratory therapy, in COVID-19 patients with acute lung failure and thus potentially increases survival.